金刚烷胺联合多奈哌齐治疗帕金森病的疗效分析

Effect analysis of amantadine combined with Donepezil in the treatment of Parkinson's disease

目的:探讨金刚烷胺联合多奈哌齐治疗帕金森病的疗效。方法:前瞻性选择2020年9月至2022年10月我院收治的76例帕金森病患者作为研究对象。采用随机数字表法将患者分为对照组和观察组,各38例。对照组采用金刚烷胺治疗;观察组采用金刚烷胺联合多奈哌齐治疗。两组均连续治疗6 m。分析比较两组治疗6 m的临床疗效,治疗前、治疗6 m的帕金森评分量表(Unified Parkinson's Disease Rating Scale,UPDRS)总评分及治疗期间的不良反应。结果:治疗6 m,观察组总有效率高于对照组(P<0.05)。治疗前,两组UPDRS总评分无明显差异(P>0.05);治疗6 m,两组UPDRS各项评分及总分较治疗前明显降低,且观察组UPDRS各项评分及总分均明显低于对照组(P<0.05)。治疗期间,两组不良反应无明显差异(P>0.05)。结论:金刚烷胺联合多奈哌齐可增强帕金森患者临床疗效,减轻帕金森病症,且不增加不良反应发生率,安全性较好,值得临床推广应用。

Objective:To investigate the efficacy of amantadine combined with Donepezil in the treatment of Parkinson's disease.Methods:76 patients with Parkinson's disease treated in our hospital from September 2020 to October 2022 were prospectively selected as research objects.The patients were divided into control group and observation group with 38 cases in each group by random number table method.The control group was treated with amantadine.Observation group was treated with amantadine combined with Donepezil.Both groups were treated continuously for 6 months.The clinical efficacy,total scores of the Unified Parkinson's Disease Rating Scale(UPDRS)before and after 6 months of treatment and adverse reactions during treatment were analyzed and compared between the two groups.Results:After 6 months of treatment,the total effective rate of observation group was higher than that of control group(P<0.05).Before treatment,there was no significant difference in UPDRS scores between the two groups(P>0.05).After 6 months of treatment,the UPDRS scores and total scores of both groups were significantly lower than those before treatment,and the UPDRS scores and total scores of the observation group were significantly lower than those of the control group(P<0.05).During treatment,there was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Amantadine combined with Donepezil can enhance the clinical efficacy of patients with Parkinson's disease and reduce the incidence of Parkinson's disease without increasing the incidence of adverse reactions.It is safe and worthy of clinical application.